Tian Xia, MD
Retina Specialist · Livingston, NJNPI 1023402260
Payments from drug & device makers
What this record shows
17 manufacturers reported payments, led by Regeneron at 58.6% of the total. Reporting peaked in 2024 at $3,675 and has fallen 79.5% since, to $753 in 2025.
Across 64 payments — averaging $90.72 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Regeneron$3K
- AbbVie$643
- Apellis Pharmaceuticals, Inc.$443
- Alcon$351
- NEW World Medical,inc.$197
- Genentech USA, Inc.$170
- plus $600 from 11 others
What the payments were for
- Consulting fees$3,32657%
- Food & beverage$2,48143%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Regeneron | 5 | $3,401 |
| AbbVie(2 entities) | 16 | $643 |
| Apellis Pharmaceuticals, Inc. | 10 | $443 |
| Alcon | 5 | $351 |
| NEW World Medical,inc. | 2 | $197 |
| Genentech USA, Inc. | 8 | $170 |
| Sight Sciences, Inc. | 1 | $145 |
| Novartis | 1 | $100 |
| Regeneron Healthcare Solutions, Inc. | 5 | $84 |
| Astellas Pharma US Inc | 4 | $75 |
| Biotissue Holdings Inc. | 1 | $58 |
| Coherus Oncology, Inc. | 1 | $34 |
| US Oncology Corporate, Inc. | 1 | $29 |
| Biogen | 1 | $28 |
| Harrow Eye, LLC | 1 | $17 |
| Amgen | 1 | $16 |
| Alimera Sciences, Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$5,806 in reported general payments places this provider in the 60th percentile of 35 retina specialist providers in New Jersey.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Prednisolone Acetate | 171 | $4,711 |
| ProlensaBromfenac Sodium | 11 | $4,104 |
| Difluprednate | 47 | $3,868 |
| Tobramycin-DexamethasoneTobramycin/Dexamethasone | 64 | $2,707 |
| Brimonidine Tartrate | 28 | $2,203 |
| Ketorolac Tromethamine | 91 | $1,803 |
| MoxifloxacinMoxifloxacin Hcl | 29 | $540 |
| Dorzolamide Hcl | 15 | $302 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 15 | $159 |
Paid to pharmacies, not to this prescriber.
Other retina specialist in Livingston
- Kurt JacksonLivingston$11K
- Eric KanterLivingston$725
- Howard FineNew Brunswick$955K
- Joshua MaliFlemington$230K
- Jonathan PrennerNew Brunswick$215K
- Leonard FeinerUnion$72K
- Daniel RothNew Brunswick$61K
- Sumit ShahNew Brunswick$41K
- Vatsal DoshiMillburn$32K
- Ravi PatelToms River$18K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.